PM
ALNY icon

Prosight Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Prosight Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5M Buy
98,080
+22,080
+29% +$6.66M 5.09% 7
2026
Q1 		$25.1M Buy
76,000
+58,891
+344% +$20M 4.12% 10
2025
Q4 		$6.8M Buy
+17,109
New +$7.57M 1.41% 23
2022
Q2 		– Sell
-22,704
Closed -$3.71M – 26
2022
Q1 		$3.71M Sell
22,704
-9,203
-29% -$1.4M 2.39% 12
2021
Q4 		$5.41M Buy
+31,907
New +$5.93M 3.24% 13

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosight Management's ALNY Position: Q2 2026 in Review

Prosight Management increased its Alnylam Pharmaceuticals (ALNY) stake by 29% in Q2 2026, buying an estimated $6.66M and bringing the position to 98,080 shares worth $29.5M. The position accounts for 5.09% of the portfolio, ranked #7.

Prosight Management first reported a position in ALNY in Q4 2021 and has held it in 5 quarters since. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Prosight Management held 98,080 shares of Alnylam Pharmaceuticals worth $29.5M as of Q2 2026.
  • Prosight Management bought 22,080 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.66M.
  • Alnylam Pharmaceuticals made up 5.09% of Prosight Management's portfolio in Q2 2026, its #7 holding.
  • Prosight Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.